MCID: MYS005
MIFTS: 63

Myositis

Categories: Muscle diseases, Genetic diseases, Neuronal diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 57 12 76 29 55 43 44 15 73
Myopathy, Familial Idiopathic Inflammatory; Iim 57
Myopathy, Familial Idiopathic Inflammatory 57
Inflammatory Disorder of Muscle 12
Iim 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
myositis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 160750
Disease Ontology 12 DOID:633
MeSH 44 D009220
NCIt 50 C27578
MedGen 42 C0027121
SNOMED-CT via HPO 69 263681008 249939004
UMLS 73 C0027121

Summaries for Myositis

MedlinePlus : 43 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Myositis, also known as myopathy, familial idiopathic inflammatory; iim, is related to inclusion body myositis and granulomatous myositis, and has symptoms including back pain, muscle cramp and muscle rigidity. An important gene associated with Myositis is HARS (Histidyl-TRNA Synthetase), and among its related pathways/superpathways are tRNA Aminoacylation and A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Simvastatin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin, and related phenotypes are proximal muscle weakness and myositis

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 76 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Description from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 34.2 APP BACE1 GNE MSTN
2 granulomatous myositis 33.7 NCAM1 PIK3C2A TTN
3 antisynthetase syndrome 32.7 HARS TARS
4 orbital plasma cell granuloma 31.5 NCAM1 PIK3C2A
5 polyglucosan body myopathy 1 with or without immunodeficiency 30.5 CAPN3 DMD
6 anterior compartment syndrome 30.4 DYSF PIK3C2A
7 compartment syndrome 30.3 CHKB MB PIK3C2A
8 localized lipodystrophy 30.3 DMD DYSF
9 muscular dystrophy-dystroglycanopathy , type c, 5 30.2 CAPN3 DYSF TTN
10 myotonia 30.0 CHKB DMD MSTN
11 limb-girdle muscular dystrophy 29.9 CAPN3 DMD DYSF TTN
12 gas gangrene 29.6 DMD MB PIK3C2A
13 neuromuscular disease 29.5 DMD GNE TTN
14 distal muscular dystrophy 29.1 CAPN3 DMD DYSF GNE TTN
15 muscular dystrophy 28.9 CAPN3 CHKB DMD DYSF GNE MSTN
16 rhabdomyosarcoma 28.9 MB MSTN MYOD1 TTN
17 myopathy 28.8 CAPN3 CHKB DMD DYSF GNE MB
18 congenital disorder of glycosylation, type iim 12.4
19 myositis ossificans 12.3
20 focal myositis 12.2
21 myositis fibrosa 12.2
22 fibrodysplasia ossificans progressiva 12.2
23 viral myositis 12.1
24 bacterial myositis 12.1
25 infective myositis 12.1
26 fungal myositis 12.1
27 idiopathic eosinophilic myositis 12.0
28 overlap myositis 12.0
29 pyomyositis 11.9
30 juvenile overlap myositis 11.9
31 idiopathic inflammatory myopathy 11.9
32 dermatomyositis 11.7
33 polymyositis 11.3
34 slc35a2-cdg 11.3
35 welander distal myopathy, swedish type 11.2
36 childhood type dermatomyositis 11.2
37 necrotizing autoimmune myopathy 11.0
38 autosomal recessive limb-girdle muscular dystrophy type 2f 10.9 CAPN3 DYSF
39 muscular dystrophy, limb-girdle, type 2j 10.9 CAPN3 TTN
40 xanthinuria, type ii 10.9
41 muscle disorders 10.9
42 foot drop 10.9
43 autosomal recessive limb-girdle muscular dystrophy type 2h 10.8 CAPN3 DYSF
44 osseous heteroplasia, progressive 10.8
45 epidemic pleurodynia 10.8
46 muscular dystrophy, limb-girdle, type 1c 10.8 DYSF MSTN
47 cardioneuromyopathy with hyaline masses and nemaline rods 10.8 DMD TTN
48 muscular dystrophy, limb-girdle, type 2h 10.7 CAPN3 DYSF TTN
49 autosomal recessive limb-girdle muscular dystrophy type 2b 10.7 CAPN3 DYSF
50 isolated hyperckemia 10.7 CAPN3 DMD

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Symptoms via clinical synopsis from OMIM:

57
Muscle:
myositis
proximal muscle weakness


Clinical features from OMIM:

160750

Human phenotypes related to Myositis:

32
# Description HPO Frequency HPO Source Accession
1 proximal muscle weakness 32 HP:0003701
2 myositis 32 HP:0100614

UMLS symptoms related to Myositis:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.75 PIK3C2A
2 Decreased viability GR00221-A-1 9.75 PIK3C2A CHKB GNE
3 Decreased viability GR00221-A-2 9.75 PIK3C2A TTN CHKB
4 Decreased viability GR00221-A-3 9.75 CHKB GNE
5 Decreased viability GR00221-A-4 9.75 PIK3C2A TTN CHKB DYSF GNE
6 Decreased viability GR00240-S-1 9.75 PIK3C2A
7 Decreased viability GR00301-A 9.75 CHKB DYSF
8 Decreased viability GR00342-S-1 9.75 TTN PIK3C2A
9 Decreased viability GR00342-S-2 9.75 PIK3C2A
10 Decreased viability GR00342-S-3 9.75 PIK3C2A TTN
11 Decreased viability GR00402-S-2 9.75 PIK3C2A TTN CHKB DYSF GNE
12 Decreased hepcidin::fluc mRNA expression GR00253-A 9.61 AARS APP BACE1 DMD DYSF MSTN
13 Decreased caspase 3/7 activity GR00318-A 9.33 APP BACE1 BACE2

MGI Mouse Phenotypes related to Myositis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.17 AARS APP BACE1 CHKB DMD DYSF
2 growth/size/body region MP:0005378 10.13 AARS APP BACE1 BACE2 CAPN3 DMD
3 cellular MP:0005384 10.11 APP BACE1 BACE2 DMD IFIH1 MB
4 cardiovascular system MP:0005385 10.1 CAPN3 DMD GNE MB MSTN MYOD1
5 homeostasis/metabolism MP:0005376 10.07 APP BACE1 CAPN3 CHKB DMD DYSF
6 mortality/aging MP:0010768 10 TTN AARS APP BACE1 BACE2 DMD
7 muscle MP:0005369 9.73 AARS APP BACE1 CAPN3 CHKB DMD
8 no phenotypic analysis MP:0003012 9.17 APP BACE1 CAPN3 DMD DYSF MSTN

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
2
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
6
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
7
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
8
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
11
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 303-98-0 5281915
12
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
13 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
15 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
16 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
17 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Rosuvastatin Calcium Phase 4,Not Applicable 147098-20-2
20 Anti-HIV Agents Phase 4,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Retroviral Agents Phase 4,Not Applicable
23 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
25 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
26
Tenofovir Phase 4 147127-20-6 464205
27 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
28 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Vaccines Phase 4,Phase 3
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Adrenocorticotropic Hormone Phase 4,Phase 2
36 beta-endorphin Phase 4,Phase 2
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Melanocyte-Stimulating Hormones Phase 4,Phase 2
41 Angiotensin II Type 1 Receptor Blockers Phase 4
42 Angiotensin Receptor Antagonists Phase 4,Not Applicable
43 Angiotensinogen Phase 4
44 Antihypertensive Agents Phase 4,Not Applicable
45 HIV Protease Inhibitors Phase 4,Not Applicable
46
Olmesartan medoxomil Phase 4 144689-63-4 130881
47
protease inhibitors Phase 4,Not Applicable
48 Serine Proteinase Inhibitors Phase 4
49 Vasoconstrictor Agents Phase 4
50 Micronutrients Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4 Simvastatin
6 Angiotensin II Blockade and Inflammation in Obesity Completed NCT01684748 Phase 4 Olmesartan medoxomil
7 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
8 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
9 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
10 Living With Statins - Interventional Exercise Study Recruiting NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
11 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
12 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Active, not recruiting NCT02403284 Phase 4 Liraglutide;Sugar Pill
13 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
14 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
15 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
16 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
17 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
18 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
19 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
20 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
21 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
22 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
23 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
24 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
25 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
26 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
27 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
28 A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection Completed NCT01527110 Phase 3 Intravenous (IV) zanamivir
29 A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children Completed NCT01218308 Phase 3
30 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
31 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
32 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
33 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
34 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
35 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Recruiting NCT03312634 Phase 3 Palovarotene
36 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
37 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Recruiting NCT03381196 Phase 3 Pimodivir 600 mg;Placebo
38 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Recruiting NCT03376321 Phase 3 Pimodivir 600 mg;Placebo
39 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
40 L-Citrulline in Patients With Post-Polio Syndrome Active, not recruiting NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
41 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Not yet recruiting NCT03486873 Phase 3 Standard of Care (SOC)
42 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
43 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
44 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
45 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
46 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
47 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
48 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
49 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
50 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

41
Bone, Testes, Skin, Lung, T Cells, Skeletal Muscle, Tongue

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 2173)
# Title Authors Year
1
Outcome of Benign Acute Childhood Myositis: The Experience of 2 Large Tertiary Care Pediatric Hospitals. ( 29851916 )
2018
2
Myositis ossificans - Another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst. ( 29661729 )
2018
3
Analysis of Clinical Manifestations and Laboratory Findings in Children with Influenza B-Associated Myositis: A Single Center Study. ( 29383210 )
2018
4
COL1A1 is a fusionpartner of USP6 in myositis ossificans - FISH analysis of six cases. ( 29980413 )
2018
5
New Developments in the Genetics of Inclusion Body Myositis. ( 29611059 )
2018
6
Pseudomalignant myositis ossificans in the breast: A case report. ( 29844904 )
2018
7
Myositis and Fasciitis: Role of Imaging. ( 29791957 )
2018
8
The diagnostic work-up of cancer-associated myositis. ( 29965856 )
2018
9
Effect of Testosterone on TRPV1 Expression in a Model of Orofacial Myositis Pain in the Rat. ( 29209900 )
2018
10
Focal myositis diffusely involving multiple masticatory muscles. ( 29400113 )
2018
11
Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. ( 29957268 )
2018
12
Paratesticular myositis ossificans of the spermatic cord. ( 29301813 )
2018
13
A Rare Case of Sarcoidosis Presenting as Diffuse Contracturing Granulomatous Myositis on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. ( 29643679 )
2018
14
Case report: A rare case of focal myositis presenting as Sartorius muscle contracture: A case report and review of literature. ( 29768366 )
2018
15
Myositis as an adverse event of immune checkpoint blockade for cancer therapy. ( 29909921 )
2018
16
6&amp;quot;-<sup>18</sup>F-Fluoromaltotriose PET Evaluation in Escherichia-Coli-Induced Myositis: is there Uptake Saturation in Control? ( 29449448 )
2018
17
Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report. ( 29692623 )
2018
18
Orbital Myositis: An Underrecognized Clinical Syndrome with a Need of Management Guidelines. ( 29334042 )
2018
19
Response to: 'Detection of myositis-specific antibodies' by Vulsteke<i>et al</i>. ( 29382639 )
2018
20
Anti-mitochondrial antibody-associated myositis with eosinophilia and dropped head. ( 29928712 )
2018
21
Diffusion weighted MRI in myositis - the value of ADC histogram analysis. ( 29436842 )
2018
22
Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-I^ autoantibodies in adult patients with myositis. ( 29884237 )
2018
23
High prevalence of chigger mite infection in a forest-specialist frog with evidence of parasite-related granulomatous myositis. ( 29502295 )
2018
24
Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis. ( 29780824 )
2018
25
Myositis in bilateral calves mimicking lymphoma on interim PET/CT in a patient with T-lymphoblastic lymphoma. ( 29590432 )
2018
26
Benign acute myositis in an adult patient. ( 29844034 )
2018
27
Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. ( 29426734 )
2018
28
Myositis Ossificans: Delayed Complication of Severe Muscle Contusion. ( 29712545 )
2018
29
Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. ( 29903623 )
2018
30
Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. ( 29706410 )
2018
31
Pattern of muscle involvement in inclusion body myositis: a sonographic study. ( 29745890 )
2018
32
Focal myositis: New insights on diagnosis and pathology. ( 29467303 )
2018
33
Health care costs and comorbidities for patients with inclusion body myositis. ( 29874942 )
2018
34
Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. ( 29529264 )
2018
35
Update on Inclusion Body Myositis. ( 29955981 )
2018
36
Effect of butylphthalide intervention on experimental autoimmune myositis in guinea pigs. ( 29387187 )
2018
37
Imported eosinophilic fever with myositis: A diagnostic challenge. ( 29802894 )
2018
38
Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. ( 29314651 )
2018
39
Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. ( 29149307 )
2018
40
Stiff Person Syndrome With Evidence of Nonspecific Focal Myositis Secondary to Sustained Muscle Contraction: A Case Report. ( 29705167 )
2018
41
Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial. ( 29775118 )
2018
42
Sporadic inclusion body myositis: magnetic resonance imaging and ultrasound characteristics. ( 29579291 )
2018
43
Benign Acute Childhood Myositis: Perplexing Complication after Acute Viral Pharyngitis. ( 29972897 )
2018
44
Eosinophilic Esophageal Myositis a Plausible Cause of Histological Changes of Primary Jackhammer Esophagus: A Case Report. ( 29311727 )
2018
45
Detection of myositis-specific antibodies. ( 29371203 )
2018
46
Myositis following spine radiosurgery for metastatic disease: a case series. ( 29372858 )
2018
47
Perinuclear antineutrophil cytoplasmic antibody-positive vasculitis, oligoarthritis, tendinitis, and myositis associated with isotretinoin in a 15-year-old boy: Case report and review of literature. ( 29644707 )
2018
48
Nocardiosis incognito: Primary cutaneous nocardiosis with extension to myositis and pleural infection. ( 29296648 )
2018
49
Eosinophilic Esophageal Myositis (EoEM) Causes Jackhammer Esophagus, Rarely Posing a Problem in the Differential Diagnosis of Eosinophilic Esophagitis. ( 29895983 )
2018
50
A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment who Developed Inclusion Body Myositis. ( 29607961 )
2018

Variations for Myositis

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.5 AARS HARS NARS TARS
2 10.52 APP BACE1
3 10.45 APP BACE1 BACE2

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 AARS APP DYSF FBL MB NARS
2 cell surface GO:0009986 9.72 APP BACE1 BACE2 DMD NCAM1
3 Z disc GO:0030018 9.54 CAPN3 DMD TTN
4 cytosol GO:0005829 9.5 AARS APP CAPN3 CHKB DMD GNE
5 astrocyte projection GO:0097449 9.26 APP DMD
6 myofibril GO:0030016 9.13 CAPN3 DMD MYOD1

Biological processes related to Myositis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.73 AARS HARS NARS TARS
2 membrane protein ectodomain proteolysis GO:0006509 9.49 BACE1 BACE2
3 skeletal muscle tissue regeneration GO:0043403 9.48 DMD MSTN
4 response to muscle activity GO:0014850 9.46 CAPN3 MSTN
5 muscle organ development GO:0007517 9.46 CAPN3 DMD MSTN MYOD1
6 amyloid-beta metabolic process GO:0050435 9.4 BACE1 BACE2
7 tRNA aminoacylation GO:0043039 9.37 AARS TARS
8 negative regulation of myoblast proliferation GO:2000818 9.32 MSTN MYOD1
9 myotube cell development GO:0014904 9.26 DMD MYOD1
10 muscle cell cellular homeostasis GO:0046716 9.13 CAPN3 DMD MSTN
11 tRNA aminoacylation for protein translation GO:0006418 8.92 AARS HARS NARS TARS

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.61 AARS CHKB GNE HARS IFIH1 NARS
2 ligase activity GO:0016874 9.46 AARS HARS NARS TARS
3 structural constituent of muscle GO:0008307 9.43 CAPN3 DMD TTN
4 aspartic-type endopeptidase activity GO:0004190 9.32 BACE1 BACE2
5 aminoacyl-tRNA ligase activity GO:0004812 8.92 AARS HARS NARS TARS

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....